This reflects what we see from the recruiter’s side of the table, which is a useful vantage point when you are planning your own next move. Moving from a large pharmaceutical company into biotech leadership is a common ambition and a frequently disappointing transition, because the capabilities that produce success in a resourced organisation are not the ones a small company needs. Biotechs hire big pharma executives for their expertise and then discover the executive cannot operate without the infrastructure that expertise was built on.
Key Takeaways
- Big pharma success depends partly on infrastructure biotechs lack.
- Biotech executives must personally produce work, not direct it.
- Capital constraint changes every decision’s character.
- Ambiguity tolerance matters more than process excellence.
- Assess honestly whether you want the work or the title.
What the Infrastructure Was Doing
In a large pharmaceutical company, an executive is supported by specialists in regulatory, biostatistics, market access, medical writing, legal, and much else, and their contribution is largely direction, judgment, and decision-making. In a biotech, many of those functions are one person, a consultant, or nobody, and the executive must personally do work that was previously delegated. Executives who have not appreciated how much the infrastructure was contributing frequently find the transition harder than expected, not because they lack capability but because the job is different work.
Capital Constraint Changes Everything
In a large company, a good idea with a sound business case generally finds funding. In a biotech, every decision is a capital allocation against a finite runway, and the question is not whether something is worth doing but whether it is worth doing instead of something else, given how many months of cash remain. This changes the character of leadership substantially: prioritisation becomes brutal, timelines are driven by financing events, and the tolerance for anything that does not advance the next milestone is low. Executives who have not operated under this constraint often underestimate its effect.
Ambiguity Over Process
Large pharmaceutical companies run on process, governance, and established ways of working, and executives who master these are effective. Biotechs frequently lack settled processes, and leaders must make decisions with incomplete information and construct approaches as they go. Executives who need clarity to act, or who respond to ambiguity by building process, can slow a small company down considerably. The relevant question in assessing yourself is whether you find undefined situations energising or frustrating, and honest answers here predict the transition better than credentials do.
Wanting the Work, Not the Title
The most useful self-assessment is whether you want the actual work of biotech leadership, writing documents yourself, doing your own analysis, working with limited support, managing personal financial risk through equity rather than salary, or whether you want a bigger title and more autonomy than your current role offers. Both are understandable, but only the first predicts success. Candidates who join biotechs primarily for the title and scope frequently leave within eighteen months, which is costly for everyone, so the honest examination is worth doing before you start interviewing.
What This Looks Like in Practice
An executive considering the move examines honestly whether they want the hands-on work rather than the title, assesses their genuine tolerance for ambiguity and capital constraint, and tests the transition by seeking evidence of what daily work will actually involve rather than relying on the role description.
The Mistake Candidates Keep Making
The most common mistake is treating the move as a step up in scope while underestimating that it is also a step down in support. The executive arrives expecting to direct and discovers they must produce, finds prioritisation under runway pressure unfamiliar, and either adapts uncomfortably or leaves. Scope is mistaken for the whole of the change.
Big Pharma vs Biotech Leadership Reality
| Dimension | Big Pharma | Biotech |
|---|---|---|
| Executive contribution | Direction and judgment | Direction plus personal production |
| Support functions | Deep specialist teams | One person, a consultant, or nobody |
| Resource decisions | Business case driven | Runway allocation, brutally prioritised |
| Process | Established and relied upon | Often absent, constructed as you go |
| Compensation risk | Largely salary and bonus | Materially equity dependent |
The Bottom Line
Moving from big pharma to biotech leadership means trading infrastructure for autonomy and doing work you previously directed, under capital constraint and ambiguity, so examine honestly whether you want that work rather than the title, since the latter motivation predicts a short and expensive tenure. The candidates who move well are rarely the ones who started looking last month; they are the ones who prepared before they needed to.
Related Reading
For more, see How to Negotiate Equity in a Biotech Executive Offer, Preparing for a Pharma C-Suite Interview, What Pharma Recruiters Wish Candidates Knew.
Frequently Asked Questions
- Q: Why is this transition harder than expected?
- A: Because big pharma executives are supported by deep specialist functions and largely provide direction, while biotech leaders must personally produce work those functions previously handled.
- Q: How does capital constraint change leadership?
- A: Every decision becomes an allocation against finite runway, so prioritisation is brutal, timelines follow financing events, and anything not advancing the next milestone is hard to justify.
- Q: What personal quality matters most?
- A: Tolerance for ambiguity, since biotechs often lack settled process and leaders must act on incomplete information rather than building process to create clarity.
- Q: How do I assess my own fit?
- A: Ask honestly whether you want the hands-on work, doing your own analysis with limited support and accepting equity-weighted risk, or primarily a larger title and more autonomy.
- Q: What happens when the fit is wrong?
- A: Executives who joined for title and scope frequently leave within eighteen months, which is costly for the company and damaging to the executive’s record.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
